Trilaciclib

Trilaciclib is an orally bioavailable, short-acting CDK4/6 inhibitor (IC50 1-4 nM) that induces reversible G1 arrest. It is researched for mitigating chemotherapy-induced myelosuppression and enhancing antitumor immunity in various cancers, with applications in both in vitro cell cycle studies and in vivo preclinical models.